CD79a Antikörper

Produktnummer ABIN7880034

Der Maus Monoklonal anti-CD79a Antikörper wird verwendet zum Nachweis von CD79a in Proben von Human. Er wurde validiert für FACS, IF und IHC (p).

Kurzübersicht für CD79a Antikörper (ABIN7880034)

Target: CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser CD79a Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), Immunofluorescence (IF), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Güteklasse: Carrier-free

Klon: ZL7-4

Produktdetails anti-CD79a Antikörper

Verwendungszweck: CD79a Antibody (azide and preservative free)

Aufreinigung: Protein G affinity chromatography

Immunogen: IgM complex isolated from Daudi cells was used as the immunogen for this CD79a antibody.

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the CD79a antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the CD79a antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Details zu CD79a

Target: CD79a (CD79A) (B-cell antigen receptor complex-associated protein alpha chain (CD79A))

Andere Bezeichnung: CD79a

Hintergrund: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.

UniProt: P11912

Pathways: BCR Signaling